The stock of Enliven Therapeutics Inc (ELVN) has seen a 12.45% increase in the past week, with a 18.94% gain in the past month, and a 55.26% flourish in the past quarter. The volatility ratio for the week is 6.70%, and the volatility levels for the past 30 days are at 6.17% for ELVN. The simple moving average for the past 20 days is 12.95% for ELVN’s stock, with a 57.67% simple moving average for the past 200 days.
Is It Worth Investing in Enliven Therapeutics Inc (NASDAQ: ELVN) Right Now?
Moreover, the 36-month beta value for ELVN is 1.08. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ELVN is 27.01M and currently, short sellers hold a 19.42% of that float. On July 31, 2024, ELVN’s average trading volume was 314.32K shares.
ELVN) stock’s latest price update
Enliven Therapeutics Inc (NASDAQ: ELVN)’s stock price has plunge by 3.33relation to previous closing price of 26.13. Nevertheless, the company has seen a 12.45% surge in its stock price over the last five trading sessions. globenewswire.com reported 2024-05-29 that BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) — Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June:
Analysts’ Opinion of ELVN
Many brokerage firms have already submitted their reports for ELVN stocks, with Robert W. Baird repeating the rating for ELVN by listing it as a “Outperform.” The predicted price for ELVN in the upcoming period, according to Robert W. Baird is $32 based on the research report published on June 11, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see ELVN reach a price target of $34. The rating they have provided for ELVN stocks is “Buy” according to the report published on April 09th, 2024.
Jefferies gave a rating of “Buy” to ELVN, setting the target price at $27 in the report published on March 29th of the previous year.
ELVN Trading at 18.36% from the 50-Day Moving Average
After a stumble in the market that brought ELVN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.43% of loss for the given period.
Volatility was left at 6.17%, however, over the last 30 days, the volatility rate increased by 6.70%, as shares surge +25.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.49% upper at present.
During the last 5 trading sessions, ELVN rose by +13.70%, which changed the moving average for the period of 200-days by +118.05% in comparison to the 20-day moving average, which settled at $24.18. In addition, Enliven Therapeutics Inc saw 95.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ELVN starting from Lyssikatos Joseph P, who proposed sale 12,000 shares at the price of $27.31 back on Jul 29 ’24. After this action, Lyssikatos Joseph P now owns shares of Enliven Therapeutics Inc, valued at $327,720 using the latest closing price.
Hohl Benjamin, the Officer of Enliven Therapeutics Inc, proposed sale 5,250 shares at $27.31 during a trade that took place back on Jul 29 ’24, which means that Hohl Benjamin is holding shares at $143,378 based on the most recent closing price.
Stock Fundamentals for ELVN
Current profitability levels for the company are sitting at:
- -211.59 for the present operating margin
- 0.3 for the gross margin
The net margin for Enliven Therapeutics Inc stands at -180.9. The total capital return value is set at -0.29. Equity return is now at value -26.14, with -24.66 for asset returns.
Based on Enliven Therapeutics Inc (ELVN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -253.12. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -54.96.
Currently, EBITDA for the company is -83.23 million with net debt to EBITDA at 1.61. When we switch over and look at the enterprise to sales, we see a ratio of 2619.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.47.
Conclusion
To wrap up, the performance of Enliven Therapeutics Inc (ELVN) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
